Palo Alto, USA | April 30, 2026
Guardant Health and Nuvalent have announced a multi-year strategic collaboration to develop companion diagnostics (CDx) and support the clinical development and commercialization of targeted cancer therapies. The partnership will leverage Guardant’s advanced tissue and liquid biopsy capabilities through its Infinity™ platform to enable biomarker-driven oncology development, marking a significant step forward in precision medicine and personalized cancer care.
Precision Oncology Collaboration Accelerates Drug Development
The collaboration is designed to integrate diagnostic innovation with targeted therapeutic development, enabling more efficient identification of patients who are most likely to benefit from specific treatments.Guardant Health will utilize its portfolio of tissue and liquid biopsy tests to support Nuvalent’s global clinical studies, enhancing trial design and patient stratification.
This approach reflects the growing reliance on biomarker-driven strategies in oncology, where precise molecular profiling plays a critical role in improving clinical outcomes. By aligning diagnostics with therapeutics, the partnership aims to accelerate regulatory approvals and optimize treatment selection.
Companion Diagnostics to Support Regulatory and Commercial Success
Advertisement
A key component of the agreement involves the development of companion diagnostic assays, which are essential for identifying appropriate patient populations and supporting regulatory submissions. Guardant and Nuvalent will evaluate opportunities to develop both tissue-based and liquid biopsy CDx solutions, which may be co-developed alongside investigational drug candidates.
These diagnostics are expected to play a crucial role in regulatory approval pathways, as they provide evidence linking biomarkers to therapeutic efficacy. The collaboration also includes plans for global commercialization of both the therapeutic candidates and associated diagnostic tools, ensuring integrated delivery of precision oncology solutions.
Leveraging Liquid Biopsy and AI-Driven Insights
Guardant’s Infinity™ platform combines liquid biopsy, tissue diagnostics, real-world data, and artificial intelligence analytics, enabling comprehensive insights into cancer biology. Liquid biopsy technology allows for non-invasive detection of tumor-derived genetic material from blood samples, offering advantages such as improved patient monitoring and reduced procedural burden.
Meanwhile, Nuvalent’s pipeline focuses on targeted small-molecule therapies designed to overcome resistance mechanisms in cancers driven by kinase mutations, including ROS1, ALK, and HER2 alterations. The integration of these technologies represents a powerful convergence of diagnostics and therapeutics, advancing the future of precision oncology.
Driving Innovation in Personalized Cancer Treatment
The collaboration underscores a broader industry trend toward co-development of drugs and diagnostics, which is becoming increasingly critical in oncology. By combining Guardant’s diagnostic expertise with Nuvalent’s targeted therapy pipeline, the partnership aims to deliver more personalized and effective cancer treatments, ultimately improving patient outcomes.
This strategy also supports global commercialization efforts, ensuring that both therapies and diagnostics can be deployed across major healthcare markets. As precision medicine continues to evolve, such collaborations are expected to play a central role in shaping next-generation cancer care.
Source: Guardant Health, Nuvalent press release
